PT  - JOURNAL ARTICLE
AU  - Stein, David
AU  - Oviedo-Orta, Ernesto
AU  - Kampman, Wendy A
AU  - McGinniss, Jennifer
AU  - Betts, George
AU  - McDermott, Margaret
AU  - Holly, Beth
AU  - Lancaster, Johnathan M
AU  - Braunstein, Ned
AU  - Yancopoulos, George D
AU  - Weinreich, David M
TI  - Compassionate Use of REGEN-COV<sup>®</sup> in Patients with COVID-19 and Immunodeficiency-Associated Antibody Disorders
AID  - 10.1101/2021.11.05.21265911
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.11.05.21265911
4099  - http://medrxiv.org/content/early/2021/11/09/2021.11.05.21265911.short
4100  - http://medrxiv.org/content/early/2021/11/09/2021.11.05.21265911.full
AB  - Background Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection, having no viable treatment options.Methods This is a retrospective analysis of patients with primary and/or secondary immunodeficiency-associated antibody disorders who received casirivimab and imdevimab (REGEN-COV®) under emergency compassionate use. The objectives were to describe safety and response to REGEN-COV, with a focus on the subset of patients who had COVID-19 duration ≥21 days prior to treatment. Quantitative (change in oxygenation status and/or viral load) and/or qualitative (physician-reported clinical status) patient outcomes data are reported.Results Outcome data are available from 64 patients who received REGEN-COV. Improvement in ≥1 outcome measure was observed in 90.6% of the overall patient group. Thirty-seven of these patients had COVID-19 duration ≥21 days prior to treatment, with a median time from RT-PCR diagnosis to REGEN-COV administration of 60.5 days. Of the 29 patients with COVID-19 duration ≥21 days prior to treatment who had available outcome data, 96.6% showed improvement in ≥1 outcome measure evaluated following use of REGEN-COV. In the 14 patients who had post-treatment RT-PCR results available, 11 (78.6%) reported a negative RT-PCR following treatment with REGEN-COV, with 5 patients (45.5%) reporting a negative RT-PCR within 5 days of treatment and 8 (72.7%) reporting a negative RT-PCR within 21 days of treatment.Conclusions In this retrospective analysis of immunodeficient patients who were granted REGEN-COV under the compassionate use program, REGEN-COV treatment was associated with rapid viral clearance and clinical improvement in the evaluable patients with long-standing COVID-19.Summary Patients with immunodeficiency-associated antibody disorders are at a higher risk of prolonged/persistent COVID-19 infection. In this retrospective analysis, compassionate use of REGEN-COV in such patients was associated with rapid viral clearance and/or clinical improvement in the evaluable patients.Competing Interest StatementICMJE disclosure forms provided by the authors are available with the full text of this article.Funding StatementThis work was supported by Regeneron Pharmaceuticals, Inc.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board (WCG IRB, Puyallup, WA; IRB tracking number 20212896) found that this research met the requirements for a waiver of consent under 45 CFR 46 116(f) and 45 CFR 46.116(d).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesQualified researchers may request access to study documents (including the clinical study report, study protocol with any amendments, blank case report form, and statistical analysis plan) that support the methods and findings reported in this manuscript. Individual anonymized participant data will be considered for sharing once the indication has been approved by a regulatory body, if there is legal authority to share the data and there is not a reasonable likelihood of participant re-identification. Submit requests to https://vivli.org/. https://vivli.org/